Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · IEX Real-Time Price · USD
0.650
-0.190 (-22.63%)
Sep 30, 2022 4:00 PM EDT - Market closed
-22.63%
Market Cap 14.96M
Revenue (ttm) 16.90M
Net Income (ttm) -22.40M
Shares Out 23.01M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 174,881
Open 0.735
Previous Close 0.840
Day's Range 0.600 - 0.855
52-Week Range 0.600 - 4.270
Beta n/a
Analysts Buy
Price Target 4.59 (+606.3%)
Earnings Date Nov 14, 2022

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licens... [Read more...]

Industry Medical Devices
IPO Date Dec 11, 2020
Employees 165
Stock Exchange NASDAQ
Ticker Symbol VVOS
Full Company Profile

Financial Performance

In 2021, VVOS's revenue was $16.89 million, an increase of 29.23% compared to the previous year's $13.07 million. Losses were -$20.29 million, 68.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 606.26% from the latest price.

Price Target
$4.59
(606.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifica...

1 month ago - GlobeNewsWire

Vivos Therapeutics Provides Update on Second Quarter Earnings Delay

Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health

1 month ago - GlobeNewsWire

Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call

LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pati...

1 month ago - GlobeNewsWire

Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

LITTLETON, Colo.--(BUSINESS WIRE)--Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

2 months ago - Business Wire

Vivos Therapeutics' SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant I...

Study Recently Presented at the SLEEP 2022 Annual Meeting Study Recently Presented at the SLEEP 2022 Annual Meeting

3 months ago - GlobeNewsWire

Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call

Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET

5 months ago - GlobeNewsWire

Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vi...

New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues New Pneusomnia Center in Toluca Lake, Calif., Will Combine...

5 months ago - GlobeNewsWire

Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Fourth Quarter Revenue Increased 33% Year-Over-Year  While Full Year Revenue Increased 29%

6 months ago - GlobeNewsWire

Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call

Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET

6 months ago - GlobeNewsWire

Fast Company Selects Vivos Therapeutics for 2022 “World's Most Innovative Companies” List

Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies of the Year Pioneer in Treating Dentofacial Ab...

6 months ago - GlobeNewsWire

Vivos Therapeutics to Participate in Upcoming Investor Conferences

HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a ...

7 months ago - GlobeNewsWire

Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improve...

Vivos' Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea Vivos' Continuous Clinical Improvement Program Yields Promising Dat...

8 months ago - GlobeNewsWire

Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space. The post Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV High...

Other symbols: GMDASBEV
8 months ago - InvestorPlace

Why Are Vivos Therapeutics Shares Surging Today?

Vivos Therapeutics Inc (NASDAQ:VVOS) announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the quarter ended December 31, 2021, v...

8 months ago - Benzinga

Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Techno...

Vivos Also Announces Improved Pricing Agreement With SleepImage

8 months ago - GlobeNewsWire

Vivos Therapeutics' mmRNA Oral Appliance Now Eligible for Medicare Reimbursement

mmRNA is the first and only appliance of its kind covered by Medicare

9 months ago - GlobeNewsWire

Vivos Therapeutics Announces Registration with Health Canada to Manufacture and Sell Sleep Disorder, Snoring and Slee...

HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing inno...

9 months ago - GlobeNewsWire

Vivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Pos...

10 months ago - GlobeNewsWire

Vivos Therapeutics to Participate at the Q4 Virtual Investor Summit

Vivos management to present at 11:45 am Eastern Time on November 17, 2021 Vivos management to present at 11:45 am Eastern Time on November 17, 2021

10 months ago - GlobeNewsWire

Vivos Therapeutics Announces 2021 Annual Breathing Wellness Conference Presented by The Vivos Institute

Dentists from around the world to learn about the innovative and life-changing treatments for patients suffering from obstructive sleep apnea and snoring Dentists from around the world to learn about th...

11 months ago - GlobeNewsWire

Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic...

HIGHLANDS RANCH, Colo., Oct. 19, 2021 /PRNewswire/ -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovativ...

11 months ago - PRNewsWire

Children in Latest Clinical Study Show Significant Reduction of Tooth Decay After Treatment with Vivos Guides

HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing inno...

11 months ago - GlobeNewsWire

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company's Technology for Obstructive ...

Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collabora...

1 year ago - GlobeNewsWire

Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

Vivos management to present at 7:00 am EDT on September 13, 2021

1 year ago - GlobeNewsWire

Implied Volatility Surging for Vivos (VVOS) Stock Options

Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research